Correlation Between Serum Levels of 25-Hydroxyvitamin D and Severity of Community-Acquired Pneumonia in Hospitalized Patients Assessed by Pneumonia Severity Index: An Observational Descriptive Study

Vasiliki E. Georgakopoulou^{1, 2}, Konstantinos Mantzouranis², Christos Damaskos^{3, 4}, Evgenia Karakou⁵, Despoina Melemini², Dimitrios Mermigkis², Georgios Petsinis², Pagona Sklapani⁶, Nikolaos Trakas⁵, Xanthi Tsiadaki²

1. Pulmonology Department, Laiko General Hospital, Athens, GRC 2. 1st Pulmonology Department, Sismanogleio Hospital, Athens, GRC 3. Renal Transplantation Unit, Laiko General Hospital, Athens, GRC 4. "N.S. Christeas" Laboratory of Experimental Surgery and Surgical Research, National and Kapodistrian University of Athens Medical School, Athens, GRC 5. Biochemistry Department, Sismanogleio Hospital, Athens, GRC 6. Cytopathology Department, Mitera Hospital, Athens, GRC

Corresponding author: Vasiliki E. Georgakopoulou, vaso_georgakopoulou@hotmail.com

Abstract

Introduction

Pneumonia severity index (PSI) is a prognostic index used for estimating the possibility of death due to community-acquired pneumonia. Vitamin D is a fat-soluble vitamin, essential for calcium and phosphate homeostasis. Vitamin D also has antimicrobial properties and according to recent studies, its deficiency may be correlated to an increased frequency of respiratory infections. The serum concentration of 25-hydroxyvitamin D (25(OH)D) is the best vitamin D status index reflecting vitamin D produced in the skin and offered from food and dietary supplements.

Methods

The study involved patients, who fulfilled the criteria of community-acquired pneumonia. The exclusion criteria were: patients <18 years old, severely immunocompromised patients, patients with tuberculosis, patients with malabsorption disorders, nursing home residents, patients with a history of malignancy, chronic renal or liver disease, patients with congestive heart failure or cerebrovascular disease, and patients receiving vitamin D as a supplement. The following parameters, recorded on admission, were evaluated: age, sex, co-morbidity, residence in a nursing home, duration of symptoms, clinical symptoms, confusion, blood gas analysis, chest radiograph (pleural effusion), and laboratory parameters. The patients were classified in risk classes according to the PSI. Blood samples were collected within the first 48 hours of hospitalization. The serum levels of 25-hydroxyvitamin D were determined by electrochemiluminescence binding assay in Roche Cobas 601 immunoassay analyzer and mean serum levels of 25-hydroxyvitamin D in each risk class were calculated. For statistical analysis, the statistical program SPSS for Windows version 17.0 (Statistical Package for the Social Sciences, SPSS Inc., Chicago, IL) was used.

Results

A total of 46 patients, 28 males and 18 females, with a mean age of 71.5 ± 17.57 years, hospitalized with community-acquired pneumonia, were included. Sixteen patients (35%) had a severe deficiency, with 25(OH)D levels <10 ng/ml, 17 patients (37%) had moderate deficiency with 25(OH)D levels between 10-20 ng/ml, and 13 patients (28%) had insufficiency with 25(OH)D levels between 20-29 ng/ml. According to the PSI, four (8.7%) patients with a mean age of 53.75 ± 15.43 years were classified as risk class I, 10 (21.7%) patients with a mean age of 54.7 ± 14.82 years as class II, 10 (21.7%) patients with a mean age of 68.41 ± 3.96 years as class III, 17 (37%) patients with a mean age of 84.82 ± 9.73 years as class IV, and five (10.9%) patients with a mean age of 80.2 ± 9.41 years as class V. The mean levels of 25(OH)D were 19.11 ± 11.24 ng/ml in class I, 16.81 ± 8.94 ng/ml in class II, 16.65 ± 9.18 ng/ml in class III, 14.76 ± 10.22 ng/ml in class IV, and 7.49 ± 4.41 ng/ml in class V. There was a positive correlation between low levels of 25(OH)D and the pneumonia severity and statistically significant difference between the mean levels of 25(OH)D in class V (7.49 ± 4.41 ng/ml) compared to overall mean levels in classes I, II, III and IV (16.15 ± 9.49 ng/ml), with $p < 0.05$.

Conclusions

According to our results, there was a positive association between low levels of 25-hydroxyvitamin D and community-acquired pneumonia severity assessed by PSI. The determination of 25-hydroxyvitamin-D status, mostly in patients >60 years old, may prevent severe community-acquired pneumonia.

Received 06/15/2020
Review began 06/24/2020
Review ended 06/27/2020
Published 07/01/2020

© Copyright 2020

Georgakopoulou et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

How to cite this article

Georgakopoulou V E, Mantzouranis K, Damaskos C, et al. (July 01, 2020) Correlation Between Serum Levels of 25-Hydroxyvitamin D and Severity of Community-Acquired Pneumonia in Hospitalized Patients Assessed by Pneumonia Severity Index: An Observational Descriptive Study. Cureus 12(7): e8947. DOI 10.7759/cureus.8947

Categories: Infectious Disease, Pulmonology, Epidemiology/Public Health

Keywords: community-acquired pneumonia, vitamin d, pneumonia severity index, nutrition, elderly

Introduction

Vitamin D is a fat-soluble vitamin that is naturally obtained from foods and is offered as a dietary supplement. It is also produced when ultraviolet rays from daylight strike the skin. Vitamin D obtained from sun exposure, food, and dietary supplements is biologically inert and undergoes two hydroxylations for activation. The first hydroxylation occurs in the liver and converts vitamin D to 25-hydroxyvitamin D (25(OH)D), also known as calcidiol, calcifediol, or 25-hydroxyvitamin D3. The second hydroxylation takes place mainly in the kidney and forms the physiologically active 1,25-dihydroxyvitamin D (1,25(OH)2D), additionally called calcitriol [1].

The main role of vitamin D is the enhancement of calcium absorption in the intestine and the maintenance of adequate serum calcium and phosphate levels to enable normal mineralization of bones. It is also useful in bone growth and bone reshaping by osteoblasts and osteoclasts [1-2]. Vitamin D sufficiency helps to prevent rickets in children and osteomalacia in adults and helps to protect older adults from osteoporosis.

Vitamin D has other roles, including modulation of cell growth, neuromuscular and immune function, and reduction of inflammation [1,3-4]. Vitamin D partially modulate numerous genes that encode proteins regulating cell proliferation, differentiation, and apoptosis [1]. The serum concentration of 25(OH)D is the best vitamin D status index, reflecting vitamin D produced in the skin and offered from food and supplements [1], and has a fairly long circulating half-life of 15 days [5].

Vitamin D has long been known to have bactericidal, bacteriostatic, and bacteriolytic properties in vivo and in vitro [6]. Vitamin D response elements are present in promoter regions of the genes encoding for the antimicrobial peptides cathelicidin and beta-defensin-2, suggesting that vitamin D plays a role in regulating their expression [7]. Antimicrobial peptides are endogenously synthesized molecules found on the mucosal and epithelial surfaces of all multicellular organisms. They are first-line defense molecules against bacterial and viral infections and they have several other immunomodulatory effects. The two major families of antimicrobial peptides are the defensins, of which there are six alpha and two beta subclasses, and cathelicidins, of which only one subtype exists in humans, the human cathelicidin antimicrobial peptide hCAP18 [8].

Community-acquired pneumonia (CAP) is common worldwide and responsible for significant morbidity and mortality [9]. Risk factors include age, sex, severity of illness, type of pneumonia, comorbidities, and nutritional status [10-11].

A possible protective effect of vitamin D against respiratory tract infections in children and adults has been reported [12-13]. Vitamin D also exerts immunomodulatory effects on these responses to the most common cause of bacterial pneumonia, *Streptococcus pneumoniae* [14], which has been associated with long-term mortality in patients with CAP [15]. The correlation between levels of vitamin D and pneumonia severity assessed by the CURB-65 index, another clinical prediction rule that has been validated for predicting mortality in community-acquired pneumonia, has also been evaluated [16-17].

The pneumonia severity index (PSI) is a clinical prediction rule that medical practitioners can use to calculate the probability of morbidity and mortality among patients with community-acquired pneumonia. The rule uses demographics (whether someone is older and is male or female), the coexistence of co-morbid illnesses, findings on physical examination and vital signs, and essential laboratory findings. According to PSI, patients can be stratified into five risk categories, risk classes I-V, and these classes could be used to predict 30-day survival [18].

Our aim is to evaluate the correlation between serum levels of 25-hydroxyvitamin D and the severity of pneumonia in patients who are hospitalized for community-acquired pneumonia assessed by PSI.

Materials And Methods

The study involved patients who fulfilled the criteria of community-acquired pneumonia. The exclusion criteria were: patients <18 years old, severely immunocompromised patients, patients with tuberculosis, patients with malabsorption disorders, nursing home residents, patients with a history of malignancy, chronic renal or liver disease, patients with congestive heart failure or cerebrovascular disease, and patients receiving vitamin D as a supplement, as these factors affect the PSI score and vitamin D levels. The following parameters, recorded on admission, were evaluated: date of presentation (month, year), age, sex, co-morbidity, residence in a nursing home, duration of symptoms, clinical symptoms (body temperature, respiratory rate, heart rate, and arterial systolic and diastolic blood pressure), pneumonia-associated confusion, blood gas analysis (pH, partial pressure of oxygen (PaO₂), partial pressure of carbon dioxide (PaCO₂), fraction of inspired oxygen (FiO₂)), chest radiograph (pleural effusion), and laboratory parameters (hematocrit, leucocyte count, band, serum creatinine, blood urea nitrogen, sodium, blood glucose). The patients were classified in risk classes according to the PSI. Blood samples were collected within the first 48

hours of hospitalization, after antibiotics initiation which doesn't affect the PSI score. The serum levels of 25-hydroxyvitamin D were determined by electrochemiluminescence binding assay in Roche Cobas 601 immunoassay analyzer and mean serum levels of 25-hydroxyvitamin D in each risk class were calculated. Vitamin D severe deficiency was defined as 25(OH)D levels <10 ng/ml, moderate deficiency as 25(OH)D levels between 10-20 ng/ml, and insufficiency as 25(OH)D levels between 20-29 ng/ml [19]. For statistical analysis, the statistical program SPSS for Windows version 17.0 (Statistical Package for the Social Sciences, Chicago, IL) was used. Continuous variables were tested for normality of distribution by the Kolmogorov-Smirnov test. For normally distributed values, descriptive results are presented as mean (standard deviation). One-way analysis of variance (ANOVA) test was used for the normal distribution variables. All p-values were two-sided and 5% was chosen as the level of statistical significance.

Results

A total of 46 patients, 28 males and 18 females, with a mean age of 71.5±17.57 years and with community-acquired pneumonia, hospitalized from March 2019 to July 2019, were included. Verbal consent was obtained from all the patients. Sixteen patients (35%) had severe deficiency with 25(OH)D levels <10 ng/ml, 17 patients (37%) had moderate deficiency with 25(OH)D levels between 10 and 20 ng/ml and 13 patients (28%) had insufficiency with 25(OH)D levels between 20 and 29 ng/ml (Table 1). According to the PSI, four (8.7%) patients with mean age 53.75±15.43 years were classified as risk class I, 10 (21.7%) patients with mean age 54.7±14.82 years as class II, 10 (21.7%) patients with mean age 68.41±3.96 years as class III, 17 (37%) patients with mean age 84.82±9.73 years as class IV, and 5 (10.9%) patients with mean age 80.2±9.41 years as class V (Table 2). The mean levels of vitamin D were 19.11±11.24 ng/ml in class I, 16.81±8.94 ng/ml in class II, 16.65±9.18 ng/ml in class III, 14.76±10.22 ng/ml in class IV, and 7.49±4.41 ng/ml in class V (Table 2). There was a positive correlation between low levels of 25(OH)D and pneumonia severity (Figure 1) and statistically significant difference between mean levels of 25(OH)D in class V (7.49±4.41 ng/ml) compared to overall mean levels in class I, II, III and IV (16.15±9.49 ng/ml) with p<0.05 (Figure 2).

Test 25(OH)D3	<10	10-20	>20
(ng/mL)	n=16	n=17	n=13
Anthropometric characteristics			
Age	74.75(20.84)	68.35(17.76)	71.61(17.57)

TABLE 1: Classification into severe deficiency, moderate deficiency, and insufficiency

PSI	I	II	III	IV	V
	n=4	n=10	n=10	n=17	n=5
Anthropometric characteristics					
Gender (male/female)	4/0	3/7	7/3	11/6	3/2
Age	53.75(15.43)	54.7(14.82)	68.4(13.96)	84.82(9.73)	80.2(9.41)
Test					
25(OH)D3	19.11(11.24)	16.81(8.94)	16.65(9.18)	14.76(10.22)	7.49(4.41)
	PSI I	Versus II	Versus III	Versus IV	Versus V
p		0.994	0.992	0.919	0.362
	PSI II	Versus I	Versus III	Versus IV	Versus V
p		0.994	1.000	0.982	0.380
	PSI III	Versus I	Versus II	Versus IV	Versus V
p		0.992	1.000	0.986	0.397
	PSI IV	Versus I	Versus III	Versus III	Versus V
p		0.919	0.982	0.986	0.554
	PSI V	Versus I	Versus II	Versus III	Versus IV
p		0.362	0.380	0.397	0.554

TABLE 2: Characteristics of study population and comparison of mean levels of 25(OH)D between PSI classes

PSI: pneumonia severity index

FIGURE 1: Correlation between mean 25(OH)D levels and PSI classes

33: Extreme Values; 46: Outlier

PSI: pneumonia severity index

FIGURE 2: Mean levels of 25(OH)D in I, II, III, IV classes as compared to mean levels of 25(OH)D in class V

Although for both PSI risk groups IV and V patients, the management is the admission of the patient and treatment with antibiotics and monitoring, class V is associated with the greatest mortality risk compared to classes I, II, III, and V.

* $p < 0.05$

PSI: pneumonia severity index

Discussion

Pneumonia severity index (PSI) is used to classify the severity of pneumonia and to decide if patients with pneumonia can be treated as outpatients or need hospitalization. A risk class I or II patient with pneumonia can be treated at home with oral antibiotics (mortality risk of 0.1% and 0.6% within 30 days, respectively). A risk class III patient, after assessment of factors, including the circumstances and social climate conditions within the patient's family and follow-up, may either be treated at home with oral antibiotics or be admitted for a short-term hospital stay (mortality risk of 2.8% within 30 days), while patients with risk class IV-V pneumonia should be hospitalized for treatment, as risk classes IV and V are associated with a mortality risk of 8.2% and 29.2% within 30 days, respectively [18].

A significant part of the antimicrobial activity of vitamin D is through the production of peptides that have antimicrobial activity and activity against endotoxins. Vitamin D triggers the expression of effective antimicrobial peptides, such as cathelicidin and β defensin, which occur in neutrophils, monocytes, natural killer (NK) cells, and epithelial cells covering the respiratory tract [20]. Immune cells such as macrophages, lymphocytes, and monocytes have vitamin D receptors (VDRs) that, with 25(OH)D stimulation, increase the expression of these peptides [21].

Cathelicidin is potent against gram-positive and gram-negative microorganisms, fungi, and mycobacteria at an assortment of pathogen entrance sites, including the skin and the respiratory and gastrointestinal mucosa [22]. Patients with 25(OH)D levels less than 20 ng/mL might be not able to completely express cathelicidin [23], which could be related to increased susceptibility to infections such as pneumonia and central line infections [24]. Another antimicrobial peptide, human beta-defensin-2 (HBD)-2, may have

exceptional utility in multidrug-resistant microorganisms from in vitro investigations [25]. Human beta-defensin-3 (HBD)-3 is an antimicrobial peptide that has an extended range of antimicrobial action against gram-positive/negative microorganisms and fungi [26].

We found a positive correlation between low serum levels of 25-hydroxyvitamin D and the severity of community-acquired pneumonia in hospitalized patients assessed by PSI. The lowest levels of 25-hydroxyvitamin D were observed in class V, with a mean value of 7.49 mg/dl in class V as compared to an overall mean value of 16.14 mg/dl in classes I, II, III and IV ($p<0.05$). As, in our study, less than 30% of the patients had a specific pathogen isolated, we cannot report if there is any particular pathogen susceptibility in patients with lower vitamin D levels and if that correlates with the PSI score.

As mentioned above, the correlation between the levels of vitamin D and pneumonia severity assessed by the CURB-65 index has also been evaluated [16-17]. CURB-65, also known as the CURB criteria, is a clinical prediction rule that has been validated for predicting mortality in community-acquired pneumonia [27].

Brance et al. reported in their study that hospitalized adults with CAP have a high percentage of severe deficiency of 25(OH)D levels, which could lead to higher CAP severity [16]. Pletz et al. found a significant inverse correlation between the serum concentration of 1,25-OH₂ vitamin D and the CURB score [17]. Talebi et al., in their prospective cohort study, examined 180 CAP patients admitted to a teaching hospital in Tehran, Iran, during 2016-2017 and found that the vitamin D status was lower in the more severe pneumonia cases than in the less ($p=0.036$) as assessed by the CURB-65 index. Vitamin D deficiency was more prevalent in patients who died than in those who lived while vitamin D concentration was negatively correlated with hospital stay duration and significantly greater in patients who survived than in those who did not ($p<0.001$) [28]. According to a study by Mamani et al., a low level of 25(OH)D was associated with a higher incidence of CAP and more severe disease assessed by the CURB-65 index [19].

The study has potential limitations. The patient's sample size is small due to these exclusions: patients <18 years old, severely immunocompromised patients, patients with tuberculosis, patients with malabsorption disorders, nursing home residents, patients with a history of malignancy, chronic renal or liver disease, patients with congestive heart failure or cerebrovascular disease and patients receiving vitamin D as a supplement. Patients receiving vitamin D as a supplement were not enrolled because we mainly wanted to investigate if vitamin D levels are associated with mortality risk, without any exogenous administration of vitamin D. In this study, 73.9% of the patients included were > 60 years old. Although patients with diseases that can affect the PSI score were excluded, the majority of the patients were older, and old age has a great impact on PSI score. Older people have lower levels of vitamin D for several reasons such as poor skin integrity, reduced time spent outdoors, decreased intake of vitamin D, reduced renal function, and medications [29]. However, the important role of vitamin D deficiency in the development and severity of community-acquired pneumonia in the elderly has been reported in numerous studies. Lu et al. investigated the correlation between the levels of 25-hydroxyvitamin D and community-acquired pneumonia in elderly patients and concluded that the older patients with community-acquired pneumonia had a severe vitamin D deficiency, indicating that low levels of vitamin D might have an important role in the occurrence of community-acquired pneumonia [30].

Conclusions

According to our results, there was a positive association between low levels of 25-hydroxyvitamin D and community-acquired pneumonia severity assessed by PSI. Aging is associated with a gradual decline in many aspects of the immune response, and waning immunity is thought to be an important risk factor for pneumonia in the elderly in combination with malnutrition and comorbidities. Although the treatment of pneumonia is antibiotics administration, the determination of 25-hydroxyvitamin-D status, mostly in patients >60 years old, during routine visits to primary care physicians, may prevent severe community-acquired pneumonia.

Additional Information

Disclosures

Human subjects: Consent was obtained by all participants in this study. **Animal subjects:** All authors have confirmed that this study did not involve animal subjects or tissue. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Institute of Medicine: Dietary Reference Intakes for Calcium and Vitamin D. Ross AC, Taylor CL, Yaktine AL, Del Valle HB (ed): The National Academies Press, Washington, DC; 2011. [10.17226/13050](https://doi.org/10.17226/13050)

2. Cranney Ann, Horsley T, O'Donnell S, et al.: Effectiveness and safety of vitamin D in relation to bone health . *Evid Rep Technol Assess.* 2007, 158:1-235.
3. Shils ME, Shike M: *Modern Nutrition in Health and Disease* . Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ (ed): Lippincott Williams & Wilkins, Philadelphia; 2006.
4. International Life Sciences Institute: *Present Knowledge in Nutrition*. Bowman BA, Russell RM (ed): International Life Sciences Institute, Washington, DC; 2006.
5. Jones G: Pharmacokinetics of vitamin D toxicity . *Am J Clin Nutr.* 2008, 88:582-586. [10.1093/ajcn/88.2.582S](#)
6. Raab W: Vitamin D—its bactericidal action . *Chest.* 1946, 12:409-415. [10.1378/chest.12.5.409](#)
7. Wang TT, Nestel FP, Bourdeau V, et al.: Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. *J Immunol.* 2004, 173: 2909-2912. [10.4049/jimmunol.173.5.2909](#)
8. Restrepo MI, Faverio P, Anzueto A: Long-term prognosis in community-acquired pneumonia . *Curr Opin Infect Dis.* 2013, 26:151-158. [10.1097/QCO.0b013e32835ebc6d](#)
9. Zasloff M: Antimicrobial peptides of multicellular organisms . *Nature.* 2002, 415:389-395. [10.1038/415389a](#)
10. Wunderink RG, Waterer GW: Clinical practice. Community-acquired pneumonia . *N Engl J Med.* 2014, 370:543-551. [10.1056/NEJMcp1214869](#)
11. Mortensen EM, Metersky ML: Long-term mortality after pneumonia . *Semin Respir Crit Care Med.* 2012, 33:319-324. [10.1055/s-0032-1315644](#)
12. Bergman P, Lindh AU, Bjorkhem-Bergman L, Lindh JD: Vitamin D and respiratory tract infections: a systematic review and meta-analysis of randomized controlled trials. *PLoS One.* 2013, 8:e65835. [10.1371/journal.pone.0065835](#)
13. Charan J, Goyal JP, Saxena D, Yadav P: Vitamin D for prevention of respiratory tract infections: a systematic review and meta-analysis. *J Pharmacol Pharmacother.* 2012, 3:300-303. [10.4103/0976-500x.103685](#)
14. Olliver M, Spelmink L, Hiew J, Meyer-Hoffert U, Henriques-Normark B, Bergman P: Immunomodulatory effects of vitamin D on innate and adaptive immune responses to *Streptococcus pneumoniae*. *J Infect Dis.* 2013, 208:1474-81. [10.1093/infdis/jit355](#)
15. Sandvall B, Rueda AM, Musher DM: Long-term survival following pneumococcal pneumonia . *Clin Infect Dis.* 2013, 56:1145-1146. [10.1093/cid/cis1207](#)
16. Brance ML, Miljevic JN, Tizziani R, et al.: Serum 25-hydroxyvitamin D levels in hospitalized adults with community-acquired pneumonia. *Clin Respir J.* 2018, 12:2220-2227. [10.1111/crj.12792](#)
17. Pletz MW, Terkamp C, Schumacher U, Rohde G, Schütte H, Welte T, Bals R: Vitamin D deficiency in community-acquired pneumonia: low levels of 1,25(OH)₂ D are associated with disease severity. *Respir Res.* 2014, 15:53. [10.1186/1465-9921-15-53](#)
18. Fine MJ, Auble TE, Yealy DM, et al.: A prediction rule to identify low-risk patients with community-acquired pneumonia. *N Engl J Med.* 1997, 336:243-250. [10.1056/NEJM199701233360402](#)
19. Mamani M, Muceli N, Reza H, Basir G, Vasheghani M, Poorolajal J: Association between serum concentration of 25-hydroxyvitamin D and community-acquired pneumonia: a case-control study. *Int J Gen Med.* 2017, 10:423-429. [10.2147/IJGM.S149049](#)
20. Ginde AA, Mansbach JM, Camargo CA Jr: Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. *Arch Intern Med.* 2009, 169:384-390. [10.1001/archinternmed.2008.560](#)
21. Schwalfenberg GK: A review of the critical role of vitamin D in the functioning of the immune system and the clinical implications of vitamin D deficiency. *Mol Nutr Food Res.* 2011, 55:96-108. [10.1002/mnfr.201000174](#)
22. Bartley J: Vitamin D: emerging roles in infection and immunity . *Expert Rev Anti Infect Ther.* 2010, 8:1359-1369. [10.1586/eri.10.102](#)
23. Bikle DD: Vitamin D and the immune system: role in protection against bacterial infection . *Curr Opin Nephrol Hypertens.* 2008, 17:348-352. [10.1097/MNH.0b013e3282ff64a3](#)
24. Routsias JG, Karagounis P, Parvulesku G, Legakis NJ, Tsakris A: In vitro bactericidal activity of human beta-defensin 2 against nosocomial strains. *Peptides.* 2010, 31:1654-1660. [10.1016/j.peptides.2010.06.010](#)
25. Suzuki Y, Inokuchi S, Takazawa K, et al.: Introduction of human β -defensin-3 into cultured human keratinocytes and fibroblasts by infection of a recombinant adenovirus vector. *Burns.* 2011, 37:109-116. [10.1016/j.burns.2010.08.004](#)
26. Ross AC, Manson JE, Abrams SA, et al.: The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab.* 2011, 96:53-58. [10.1210/jc.2010-2704](#)
27. Lim WS, van der Eerden MM, Laing R, et al.: Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. *Thorax.* 2003, 58:377-382. [10.1136/thorax.58.5.377](#)
28. Talebi F, Rasooli nejad M, Yaseri M, Hadadi A: Association of vitamin D status with the severity and mortality of community-acquired pneumonia in Iran during 2016-2017: a prospective cohort study. *Rep Biochem Mol Biol.* 2019, 8:85-90.
29. Meehan M, Penckofer S: The role of vitamin D in the aging adult . *J Aging Gerontol.* 2014, 2:60-71. [10.12974/2309-6128.2014.02.02.1](#)
30. Lu D, Zhan J, Ma C, Yue Y, Zou Z, Yu C, Yin F: Link between community-acquired pneumonia and vitamin D levels in older patients. *Z Gerontol Geriat.* 2018, 51:435-439. [10.1007/s00391-017-1237-z](#)